Patents by Inventor Stefan Jaekel

Stefan Jaekel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190118861
    Abstract: A motor vehicle steering assembly having a steering shaft which extends from a vehicle steering wheel to a pinion and is rotatable about a steering axis, a combined steering angle and steering torque sensor which includes sensor elements connected to the steering shaft for joint rotation therewith, and a housing upper part of a multipart steering gear housing which closes, on the steering wheel side, a housing lower part for receiving the pinion, the housing lower part being open in the axial direction towards the vehicle steering wheel, the combined steering angle and steering torque sensor being received in the housing upper part, the steering shaft extending through the housing upper part, and the sensor elements connected to the steering shaft for joint rotation therewith being directly adjacent to the housing upper part.
    Type: Application
    Filed: April 19, 2017
    Publication date: April 25, 2019
    Applicant: TRW Automotive GmbH
    Inventors: Stefan Jaekel, Robert Engler
  • Publication number: 20160279213
    Abstract: The invention relates to a therapeutically effective truncated survivin and its therapeutic use as vaccine in a liposomal preparation, wherein the survivin fragment is preferably gluconoylated, and said liposomal preparation elicits in-vivo anti-tumor activity. The invention is directed, in more detail, to a cancer vaccine comprising a fragment of human survivin that is specifically effective in conjunction with an lipid adjuvant. The invention relates in more detail to a liposomal vaccine delivery system comprising an active truncated survivin molecule as tumor antigen and a chiral cationic lipid, for example R-DOTAP acting as adjuvant, which is part of the liposome preparation, wherein the liposomal drug delivery system is optimized with regard to its lipid and adjuvant components, physical or physicochemical parameters, and the final therapeutic efficacy of the released truncated survivin molecules.
    Type: Application
    Filed: December 16, 2014
    Publication date: September 29, 2016
    Inventors: Simon Geissler, Patrizia Boniforte, Joerg Plaschke, Markus Weigandt, Stefan Jaekel, Roland Kellner, Thomas Rysiok, Dirk Mueller-Pompalla, Kenneth Hance
  • Patent number: 8957020
    Abstract: This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing obesity, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the animal or human subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing obesity.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: February 17, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Arnd Steuernagel, Karsten Eulenberg, Guenter Broenner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jaekel, Christoph Meyer
  • Patent number: 8828934
    Abstract: This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing a pancreatic malfunction, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing a pancreatic malfunction.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: September 9, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Arnd Steuernagel, Karsten Eulenberg, Guenter Broenner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jaekel, Christoph Meyer
  • Patent number: 8697713
    Abstract: The present invention relates to novel pyrrolopyrimidine compounds of the general formula (1) and pharmaceutical compositions comprising said pyrrolopyrimidine compounds. Moreover, the present invention relates to the use of the pyrrolopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Grant
    Filed: July 10, 2007
    Date of Patent: April 15, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Stefan Jäkel, Tanja Reuter, Stephen Murfin, Thomas Stephen Coulter, Steven Taylor
  • Patent number: 8633201
    Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: January 21, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Babette Aicher, Thomas Stephen Coulter, Stefan Jaekel, Arndt-René Kelter, Stephen Murfin, Tanja Reuter, Steven Taylor
  • Publication number: 20120045452
    Abstract: This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing a pancreatic malfunction, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing a pancreatic malfunction.
    Type: Application
    Filed: September 26, 2011
    Publication date: February 23, 2012
    Applicant: DeveloGen Aktiengesellschaft fuer Entwicklungsbiologische Forschung
    Inventors: Arnd Steuernagel, Karsten Eulenberg, Günter Brönner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jäkel, Christoph Meyer
  • Patent number: 8076098
    Abstract: The present invention discloses Mnk homologous proteins regulating the energy homeostasis, the metabolism of triglycerides, and/or is contributing to membrane stability and/or function of organelles, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders related to body-weight regulation and thermogenesis, for example, but not limited to, metabolic diseases such as obesity, as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, and sleep apnea, and disorders related to ROS defence, such as diabetes mellitus, neurodegenerative disorders, and cancer, e.g. cancers of the reproductive organs, and others.
    Type: Grant
    Filed: July 16, 2008
    Date of Patent: December 13, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Arnd Steuernagel, Karsten Eulenberg, Guenter Broenner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jaekel, Christoph Meyer
  • Patent number: 8071607
    Abstract: The present invention relates to the use of pyrazolopyrimidine compounds for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: December 6, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Stephen Coulter, Steven Taylor, Stephen Murfin, Valery Thammalaksa, Babette Aicher, Stefan Jaekel, Tanja Reuter
  • Publication number: 20110159568
    Abstract: The present invention relates to crystalline Mnk-1 and Mnk-2 kinases and, in particular, to the crystal structure of Mnk-1 and Mnk-2 kinase domain.
    Type: Application
    Filed: February 8, 2011
    Publication date: June 30, 2011
    Inventors: Markus Wahl, Ralf Jauch, Kay Schreiter, Stefan Jäkel
  • Patent number: 7943357
    Abstract: The present invention relates to crystalline Mnk-1 and Mnk-2 kinases and, in particular, to the crystal structure of Mnk-1 and Mnk-2 kinase domain.
    Type: Grant
    Filed: March 8, 2006
    Date of Patent: May 17, 2011
    Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V., Boehringer Ingelheim International GmbH
    Inventors: Markus Wahl, Ralf Jauch, Kay Schreiter, Stefan Jäkel
  • Publication number: 20100105708
    Abstract: The present invention relates to novel pyrrolopyrimidine compounds of the general formula (1) and pharmaceutical compositions comprising said pyrrolopyrimidine compounds. Moreover, the present invention relates to the use of the pyrrolopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: July 10, 2007
    Publication date: April 29, 2010
    Applicant: DEVELOGEN AKTIENGESELLSCHAFT
    Inventors: Stefan Jäkel, Tanja Reuter, Stephen Murfin, Thomas Stephen Coulter, Steven Taylor
  • Publication number: 20100056548
    Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: April 10, 2007
    Publication date: March 4, 2010
    Applicant: DEVELOGEN AKTIENGESELLSCHAFT
    Inventors: Babette Aicher, Thomas Stephen Coulter, Stefan Jaekel, Arndt-René Kelter, Stephen Murfin, Tanja Reuter, Steven Taylor
  • Publication number: 20090163520
    Abstract: The present invention relates to the use of pyrazolopyrimidine compounds for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: December 22, 2005
    Publication date: June 25, 2009
    Inventors: Thomas Stephen Coulter, Stephen Taylor, Stephen Murfin, Valery Thammalaksa, Babette Aicher, Stefan Jaekel, Tanja Reuter